BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:SAR446268 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of SAR446268\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06844214-11342@assetmemo.bio
DTSTAMP:20261121T004105Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:SAR446268: Phase 1/2 readout est. (NCT06844214)
DESCRIPTION:SAR446268\, phase 1/2\, Myotonic Dystrophy Type 1.\nStudy: A St
 udy to Investigate the Safety\, Tolerability\, and Efficacy of SAR446268\,
  an Adeno-associated Viral Vector-mediated Gene Therapy in Participants Ag
 ed 10 to 55 Years of Age With Non-congenital Myotonic Dystrophy Type 1\nEs
 timated primary completion: 28 February 2029. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/sar446268#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06844214
URL:https://assetmemo.bio/drug/sar446268#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
